| TITLE |
DATE |
| The Medicines Company Invests Equity Stake in GeNO, LLC, Nitric Oxide
Delivery and Technology Company |
5-Dec-2011 |
| The Medicines Company to Participate in the 2011 Deutsche Bank
BioFEST |
30-Nov-2011 |
| The Medicines Company's MDCO-216 (ApoA-I Milano Complex) Demonstrates Capacity to Clear Cholesterol From Cells in Preclinical Model |
14-Nov-2011 |
| German Researchers Reaffirm Utility of Angiomax(R)/Angiox(R)
(Bivalirudin) in High Risk PCI Patients |
13-Nov-2011 |
| Scripps Health and The Medicines Company Announce Late Breaking
BRIDGE Trial Results Presented at TCT |
9-Nov-2011 |
| First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in
Transcatheter Aortic Valve Interventions Reported at TCT |
8-Nov-2011 |
| The Medicines Company Announces Schedule of Events at Upcoming
Transcatheter Cardiovascular Therapeutics (TCT) Conference |
2-Nov-2011 |
| For Immediate Release to US Investors: The Medicines Company and
Daiichi Sankyo Announce Angiox(R) (Bivalirudin) Co-Promotion for
Germany |
28-Oct-2011 |
| The Medicines Company Reports Third Quarter 2011 Results |
26-Oct-2011 |
| The Medicines Company's MDCO-2010 Meets Clinical Trial Objectives in
Patients Undergoing Open-Heart Surgery |
15-Oct-2011 |
| The Medicines Company to Announce Third Quarter 2011 Financial
Results on Wednesday, October 26, 2011 |
12-Oct-2011 |
| The Medicines Company Launches New Formulation of Cleviprex(R) (Clevidipine) Injectable Emulsion |
3-Oct-2011 |
| The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent
Litigations With Teva |
3-Oct-2011 |
| The Medicines Company to Participate in the Jefferies 2011 Global
Healthcare Conference in London |
22-Sep-2011 |
| The Medicines Company to Participate in the UBS Global Life Sciences
Conference |
14-Sep-2011 |
| The Medicines Company Launches 50mL Ready-to-Use Formulation of
Argatroban Injection |
13-Sep-2011 |
| The Medicines Company Appoints Glenn P. Sblendorio to Board of
Directors |
28-Jul-2011 |
| The Medicines Company Reports Second Quarter and First Half 2011
Results |
27-Jul-2011 |
| NICE Endorses Bivalirudin for Heart Attack Patients |
26-Jul-2011 |
| The Medicines Company to Announce Second Quarter 2011 Financial
Results on Wednesday, July 27, 2011 |
13-Jul-2011 |
| RELAZIONE ITALIANA SUI RISULTATI DELLO STUDIO GLOBALE SULL'INFARTO |
20-Jun-2011 |
| RESULTATS HORIZONS-AMI 3-ANS PUBLIES DANS "THE LANCET" |
16-Jun-2011 |
| DEUTSCHE EXPERTEN FÜR INNERE MEDIZIN BERICHTEN ÜBER GLOBALE HERZINFARKTSTUDIE / HORIZONS-AMI 3-JAHRE RESULTATE IM THE LANCET VERÖFFENTLICHT |
16-Jun-2011 |
| BRITISH MEDICAL LEADERS REPORT RESULTS OF GLOBAL HEART ATTACK STUDY |
16-Jun-2011 |
| Ligand and The Medicines Company Agree to Worldwide License for
Proprietary Captisol(R)-Enabled Intravenous Formulation of Clopidogrel |
3-Jun-2011 |
| The Medicines Company to Participate in the Jefferies 2011 Global
Healthcare Conference |
31-May-2011 |
| The Medicines Company Engages in Stent for Life Initiative in Europe |
20-May-2011 |
| The Medicines Company to Participate in the 2011 Bank of America
Merrill Lynch Health Care Conference |
5-May-2011 |
| The Medicines Company Appoints John C. Kelly to Board of Directors |
28-Apr-2011 |
| The Medicines Company Reports First Quarter 2011 Earnings per Share
of $0.45 vs. $0.18 in 2010 |
27-Apr-2011 |
| The Medicines Company to Participate in the Deutsche Bank 36th Annual
Health Care Conference |
25-Apr-2011 |
| The Medicines Company to Announce First Quarter 2011 Financial Results on Wednesday, April 27, 2011 |
13-Apr-2011 |
| The Medicines Company to Participate in the Citi 2011 Health Care
Conference and the 2011 RBC Capital Markets Healthcare Conference |
24-Feb-2011 |
| The Medicines Company Reports Fourth Quarter Revenue Rises 17.2% to
$119.7 Million |
16-Feb-2011 |
| The Medicines Company and WilmerHale Law Firm Reach Settlement
Agreement |
14-Feb-2011 |
| The Medicines Company to Announce Fourth Quarter and Full Year 2010
Financial Results on Wednesday, February 16, 2011 |
2-Feb-2011 |
| The Medicines Company to Participate in the 29th Annual JP Morgan Healthcare Conference |
5-Jan-2011 |
| The Medicines Company Reaches Agreement With FDA on Special Protocol
Assessment for Oritavancin Phase 3 Trials |
29-Nov-2010 |
| The Medicines Company Reports Third Quarter 2010 Financial Results |
27-Oct-2010 |
| The Medicines Company to Participate in Newsmakers in the Biotech
Industry Conference |
15-Oct-2010 |
| The Medicines Company to Announce Third Quarter 2010 Financial
Results on Wednesday, October 27, 2010 |
13-Oct-2010 |
| U.S. Government Does Not Appeal Decision in Favor of The Medicines
Company in PTO Litigation |
5-Oct-2010 |
| Angiomax(R)/Angiox(R) (Bivalirudin) Reduced Cardiac Mortality by 44%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty |
25-Sep-2010 |
| The Medicines Company to Participate in the UBS Global Life Sciences
Conference |
15-Sep-2010 |
| The Medicines Company Announces APP Motion to Intervene Denied |
10-Sep-2010 |
| The Medicines Company Provides PTO Litigation Update |
9-Sep-2010 |
| U.S. PTO Grants the Medicines Company One-Year Interim Patent
Extension |
6-Aug-2010 |
| The Medicines Company Announces Decision in PTO Suit |
3-Aug-2010 |
| The Medicines Company Reports Second Quarter 2010 Financial Results |
28-Jul-2010 |
| The Medicines Company to Announce Second Quarter 2010 Financial
Results on Wednesday, July 28, 2010 |
14-Jul-2010 |
| The Medicines Company Provides PTO Litigation Update |
21-May-2010 |
| The Medicines Company to Participate in the 2010 Citi Global Health
Care Conference |
19-May-2010 |
| The Medicines Company to Participate in the Bank of America Merrill
Lynch 2010 Health Care Conference |
5-May-2010 |
| The Medicines Company Announces Option Grants Under NASDAQ
Marketplace Rule 5635 |
29-Apr-2010 |
| The Medicines Company to Participate in the Deutsche Bank 35th Annual
Health Care Conference |
28-Apr-2010 |
| FOR U.S. AUDIENCES ONLY: The Medicines Company Reports First Quarter
2010 Financial Results |
28-Apr-2010 |
| FOR US AUDIENCES ONLY: The Medicines Company to Announce First
Quarter 2010 Financial Results on Wednesday, April 28, 2010 |
21-Apr-2010 |
| The Medicines Company Files Follow Up PTO Lawsuit |
26-Mar-2010 |
| The Medicines Company Provides Update on PTO Litigation |
19-Mar-2010 |
| The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter |
17-Mar-2010 |
| The Medicines Company Announces Decision in PTO and FDA Litigation |
16-Mar-2010 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
26-Feb-2010 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
17-Feb-2010 |
| For U.S. Audiences Only: The Medicines Company Reports Full Year and
Fourth Quarter 2009 Financial Results |
17-Feb-2010 |
| For US Audiences Only: The Medicines Company to Announce Fourth
Quarter and Full Year 2009 Financial Results on Wednesday, February
17, 2010 |
9-Feb-2010 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
15-Jan-2010 |
| The Medicines Company to Participate in the 28th Annual JP Morgan Healthcare Conference |
5-Jan-2010 |
| The Medicines Company Files Additional Patent Infringement Lawsuits |
4-Jan-2010 |
| / CORRECTION -- The Medicines Company Acquires ApoA-I Milano From
Pfizer |
22-Dec-2009 |
| The Medicines Company Issues a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter |
16-Dec-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
15-Dec-2009 |
| The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures |
1-Dec-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
30-Nov-2009 |
| The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI |
15-Nov-2009 |
| Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage |
12-Nov-2009 |
| The Medicines Company Reports Third Quarter 2009 Financial Results |
28-Oct-2009 |
| The Medicines Company Announces Positive CHMP Opinion for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures |
23-Oct-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
15-Oct-2009 |
| The Medicines Company Files Patent Infringement Lawsuits |
8-Oct-2009 |
| The Medicines Company Announces Second New Patent Issuance for Angiomax(R) |
8-Oct-2009 |
| The Medicines Company Announces Preliminary Third Quarter 2009 Top Line Results |
6-Oct-2009 |
| The Medicines Company Announces the Resignation of Its Chief Operating Officer |
2-Oct-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
30-Sep-2009 |
| The Medicines Company Licenses Innovative New Formulation of Argatroban; Gains Strategic Complement to Angiomax Franchise and Potential Near Term Revenue Opportunity |
29-Sep-2009 |
| Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty |
25-Sep-2009 |
| The Medicines Company to Participate in the UBS Global Life Sciences Conference |
16-Sep-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
15-Sep-2009 |
| The Medicines Company Receives Paragraph IV Notifications |
4-Sep-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
2-Sep-2009 |
| The Medicines Company Announces New Patent Issuance for Angiomax(R) |
2-Sep-2009 |
| The Medicines Company Announces New Publication of Data Showing Angiomax(R) Reduces Cardiac Mortality and Improves Overall Survival |
31-Aug-2009 |
| The Medicines Company Withdraws European Marketing Application for 3-7 Day Daily Dose Oritavancin Therapy |
20-Aug-2009 |
| The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 5635 |
14-Aug-2009 |
| The Medicines Company Responds to Incorrect News Reports |
10-Aug-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
31-Jul-2009 |
| The Medicines Company Reports Second Quarter 2009 Financial Results |
29-Jul-2009 |
| The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor |
23-Jul-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
15-Jul-2009 |
| The Medicines Company to Announce Second Quarter 2009 Financial Results on Wednesday, July 29, 2009 |
15-Jul-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
30-Jun-2009 |
| FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R) |
19-Jun-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
16-Jun-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
1-Jun-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
15-May-2009 |
| The Medicines Company to Participate in the Deutsche Bank Health Care Conference |
15-May-2009 |
| The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor |
13-May-2009 |
| The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 4350 |
30-Apr-2009 |
| The Medicines Company Reports First Quarter 2009 Financial Results |
29-Apr-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
15-Apr-2009 |
| The Medicines Company to Announce First Quarter 2009 Financial Results on Wednesday, April 29, 2009 |
15-Apr-2009 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
2-Apr-2009 |
| The Medicines Company EU Filing Accepted for Cleviprex(R) for the Treatment of Acute Hypertension |
26-Mar-2009 |
| The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation |
26-Feb-2009 |
| The Medicines Company Announces Completion of Tender Offer for Shares of Targanta Therapeutics |
25-Feb-2009 |
| The Medicines Company Reports Full Year and Fourth Quarter 2008 Financial Results |
18-Feb-2009 |
| The Medicines Company to Announce Fourth Quarter and Full Year 2008 Financial Results on Wednesday, February 18, 2009 |
4-Feb-2009 |
| The Medicines Company Commences Tender Offer for All Outstanding Shares of Targanta Therapeutics |
27-Jan-2009 |
| The Medicines Company to Acquire Targanta Therapeutics |
12-Jan-2009 |
| The Medicines Company to Participate in the 27th Annual JP Morgan Healthcare Conference |
6-Jan-2009 |
| New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderate and High-Risk ACS Patients |
18-Nov-2008 |
| The Medicines Company Reports Third Quarter 2008 Financial Results |
22-Oct-2008 |
| Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients |
21-Oct-2008 |
| Angiomax(R) Reduced Cardiac Mortality by 43 Percent and Improved Overall Survival by 31 Percent at One-Year in HORIZONS-AMI Trial |
15-Oct-2008 |
| The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting |
14-Oct-2008 |
| The Medicines Company to Announce Third Quarter 2008 Financial Results on Wednesday, October 22, 2008 |
8-Oct-2008 |
| New Publication Shows Cleviprex(TM) Provides More Precise Blood Pressure Control in Cardiac Surgery Patients |
3-Oct-2008 |
| New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients |
3-Sep-2008 |
| ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology |
26-Aug-2008 |
| New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension |
26-Aug-2008 |
| The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH |
5-Aug-2008 |
| The Medicines Company's Cleviprex(TM) Receives FDA Approval |
4-Aug-2008 |
| The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance |
23-Jul-2008 |
| New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery |
14-Jul-2008 |
| The Medicines Company to Announce Second Quarter 2008 Financial Results on Wednesday, July 23, 2008 |
9-Jul-2008 |
| Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses |
20-Jun-2008 |
| The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations |
17-Jun-2008 |
| The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference |
5-Jun-2008 |
| The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 |
3-Jun-2008 |
| Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis from VELOCITY Trial |
29-May-2008 |
| The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing |
28-May-2008 |
| Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients |
22-May-2008 |
| The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 |
15-May-2008 |
| Results Published in JACC Show Clinical Advantage of Switching to Angiomax from Heparin in Acute Coronary Syndrome Patients Undergoing Early Invasive Treatment |
5-May-2008 |
| The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 |
30-Apr-2008 |
| The Medicines Company Reports First Quarter 2008 Financial Results |
23-Apr-2008 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
15-Apr-2008 |
| The Medicines Company to Announce First Quarter 2008 Financial Results on Wednesday, April 23, 2008 |
9-Apr-2008 |
| Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors |
29-Mar-2008 |
| The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 |
14-Mar-2008 |
| The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 |
15-Feb-2008 |
| The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results |
13-Feb-2008 |
| Cleviprex(TM) Demonstrated Rapid, Precise Blood Pressure Control in High-Risk Patients, According to New Analyses |
5-Feb-2008 |
| Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis |
4-Feb-2008 |
| The Medicines Company Announces Multiple Presentations at Upcoming Society of Critical Care Medicine (SCCM) Annual Meeting |
1-Feb-2008 |
| The Medicines Company to Announce Fourth Quarter and Full Year 2007 Financial Results on Wednesday, February 13, 2008 |
30-Jan-2008 |
| The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS) |
29-Jan-2008 |
| The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 |
16-Jan-2008 |
| James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care |
7-Jan-2008 |
| The Medicines Company to Participate in the 26th Annual JP Morgan Healthcare Conference |
31-Dec-2007 |
| The Medicines Company to Participate in The RBC Capital Markets 2007 Healthcare Conference |
5-Dec-2007 |
| Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results |
4-Dec-2007 |
| CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes |
19-Nov-2007 |
| The Medicines Company Reports Third Quarter 2007 Financial Results |
24-Oct-2007 |
| Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients |
24-Oct-2007 |
| Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension |
23-Oct-2007 |
| The Medicines Company to Announce Third Quarter 2007 Financial Results on Wednesday, October 24, 2007 |
17-Oct-2007 |
| Improved Perioperative Blood Pressure Control Associated with Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients |
15-Oct-2007 |
| FDA Accepts sNDA for Expanded Use of Angiomax(R) (bivalirudin) |
24-Sep-2007 |
| The Medicines Company to Present at the UBS 2007 Global Life Sciences Conference |
20-Sep-2007 |
| FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension |
14-Sep-2007 |
| The Medicines Company to Present at the Bear Stearns 20th Annual Healthcare Conference |
5-Sep-2007 |
| CORRECTING and REPLACING Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty |
3-Sep-2007 |
| The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data |
7-Aug-2007 |
| The Medicines Company Reports Second Quarter and First Half 2007 Financial Results |
25-Jul-2007 |
| The Medicines Company to Announce Second Quarter 2007 Financial Results on Wednesday, July 25, 2007 |
11-Jul-2007 |
| The Medicines Company Reacquires Angiox(R) (Bivalirudin) Rights in Europe from Nycomed |
2-Jul-2007 |
| The Medicines Company to Present at Bank of America 2007 Health Care Conference |
22-May-2007 |
| The Medicines Company to Present at Citigroup's Global Healthcare Conference |
15-May-2007 |
| The Medicines Company to Present at Morgan Stanley Global Healthcare Unplugged Conference |
27-Apr-2007 |
| The Medicines Company Reports First Quarter 2007 Financial Results |
18-Apr-2007 |
| The Medicines Company to Announce First Quarter 2007 Financial Results on Wednesday, April 18, 2007 |
11-Apr-2007 |
| The Medicines Company Elects Hiroaki Shigeta to Board of Directors |
11-Apr-2007 |
| Pivotal Phase III Findings With Investigational Drug Cleviprex(TM) (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery |
27-Mar-2007 |
| Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery |
27-Mar-2007 |
| ACUITY One-Year Findings Meet All Primary Endpoints in Favor of Angiomax(R) (Bivalirudin) Alone Treatment Group |
26-Mar-2007 |
| The Medicines Company Products Angiomax(R) (bivalirudin) and Cleviprex(TM) (clevidipine) Featured in Three Late Breaking Trials at American College of Cardiology Annual Scientific Session |
15-Mar-2007 |
| The Medicines Company Supports Landmark Patient Observational Study and Clinical Survey on Acute Severe Hypertension |
19-Feb-2007 |
| The Medicines Company Reports Fourth Quarter and Full Year 2006 Financial Results |
14-Feb-2007 |
| The Medicines Company to Announce Fourth Quarter and Full Year 2006 Financial Results on Wednesday, February 14, 2007 |
7-Feb-2007 |
| The Medicines Company Determines Not to Proceed with Proposed Offering |
24-Jan-2007 |
| The Medicines Company Announces Proposed Offering of Common Stock |
16-Jan-2007 |
| The Medicines Company's Cleviprex(TM) (Clevidipine) Phase III Safety Trials Meet Pre-Specified Objectives |
8-Jan-2007 |
| The Medicines Company to Present at the 25th Annual JP Morgan Healthcare Conference |
2-Jan-2007 |
| The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results |
22-Nov-2006 |
| The Medicines Company to Present at the Annual 2006 Stanford Growth Conference |
7-Nov-2006 |
| The Medicines Company Reports Third Quarter 2006 Financial Results |
25-Oct-2006 |
| The Medicines Company to Announce Third Quarter 2006 Financial Results on Wednesday, October 25, 2006 |
10-Oct-2006 |
| The Medicines Company Commences Phase III Clinical Trial of Cangrelor |
4-Oct-2006 |
| The Medicines Company Completes Clevidipine Phase III Safety Trials and Initiates Phase III Severe Hypertension Trial; ECLIPSE Enrollment Complete, First Patient Enrolled in VELOCITY |
11-Sep-2006 |
| The Medicines Company to Present at Bear Stearns and UBS Conferences |
5-Sep-2006 |
| The Medicines Company Reports Second Quarter and First Half 2006 Financial Results; Second Quarter Net Revenues Increase 39% Compared to Second Quarter 2005; Second Quarter Net Income of $10.9 Million |
25-Jul-2006 |
| The Medicines Company to Announce Second Quarter 2006 Financial Results on Tuesday, July 25, 2006; Conference Call to Be Held at 8:30 A.M. EDT |
12-Jul-2006 |
| The Medicines Company to Present at Pacific Growth Equities and Needham & Company |
7-Jun-2006 |
| The Medicines Company to Present at Bank of America 2006 Health Care Conference |
12-May-2006 |
| The Medicines Company to Present at Deutsche Bank and Morgan Stanley Conferences |
26-Apr-2006 |
| The Medicines Company Reports First Quarter 2006 Financial Results |
19-Apr-2006 |
| The Medicines Company to Present at UBS Global Specialty Pharmaceuticals Conference |
18-Apr-2006 |
| The Medicines Company to Announce First Quarter 2006 Financial Results on Wednesday, April 19, 2006; Conference Call to be Held at 8:30 a.m. EDT |
12-Apr-2006 |
| The Medicines Company Commences Patient Enrollment in Pivotal Phase III Clinical Trial of Cangrelor; Novel Intravenous Antiplatelet Agent Described in March Issue of American Heart Journal |
4-Apr-2006 |
| Angiomax® (bivalirudin) Monotherapy Superior to Heparins Plus GP IIb/IIIa Combination for Net Clinical Outcome in ACUITY Trial |
12-Mar-2006 |
| The Medicines Company Invites Investors To ACC Webcasts |
8-Mar-2006 |
| The Medicines Company Announces Glenn Sblendorio to Be New Chief Financial Officer; Steve Koehler to Depart as Chief Financial Officer on March 17, 2006 |
6-Mar-2006 |
| The Medicines Company Reports Fourth Quarter and Full Year 2005 Financial Results |
15-Feb-2006 |
| The Medicines Company to Announce Fourth Quarter and Full Year 2005 Financial Results on Wednesday, February 15, 2006; Conference Call to be held at 8:30 am EST |
8-Feb-2006 |
| The Medicines Company to Present at the 24th Annual JP Morgan Healthcare Conference |
3-Jan-2006 |
| The Medicines Company Completes Enrollment of 13,800-Patient ACUITY Trial of Angiomax(R) (bivalirudin); ACUITY One of the Largest Global Clinical Trials Ever Conducted to Evaluate Anticoagulants Used In ACS Patients |
7-Dec-2005 |
| FDA Approves Expansion of Angiomax(R) (Bivalirudin) Label to Include Patients with or at Risk of HIT/HITTS Undergoing PCI; HIT/HITTS Places Patients at Higher Risk of Life-Threatening Complications |
1-Dec-2005 |
| Angiomax(R) (Bivalirudin) Recommended for Use in Percutaneous Coronary Interventions in Updated Guidelines from American College of Cardiology and American Heart Association |
15-Nov-2005 |
| The Medicines Company to Present at CIBC World Markets Sixteenth Annual Healthcare Conference |
1-Nov-2005 |
| The Medicines Company Reports Third Quarter Financial Results |
19-Oct-2005 |
| The Medicines Company Resumes Clevidipine Phase III Program; Phase III Interim Data Review Affirms Safety Profile |
19-Oct-2005 |
| The Medicines Company to Announce Third Quarter 2005 Financial Results on Wednesday, October 19, 2005; Conference Call to Be Held at 8:30 A.M. EDT |
12-Oct-2005 |
| The Medicines Company Lowers 2005 Guidance; Reports Preliminary Third Quarter Results |
5-Oct-2005 |
| The Medicines Company Appoints Melvin Spigelman, M.D. to Board of Directors |
29-Sep-2005 |
| The Medicines Company to Present at UBS Global Life Sciences Conference |
23-Sep-2005 |
| The Medicines Company to Present at Bear Stearns 18th Annual Healthcare Conference |
7-Sep-2005 |
| The Medicines Company to Present at Roth Capital Partners |
31-Aug-2005 |
| The Medicines Company to Present at Banc of America Conference |
22-Jul-2005 |
| The Medicines Company Reports Second Quarter and First Half 2005 Financial Results; FDA Approval of New Angiomax(R) (Bivalirudin) Label, Sales Force Expansion and Major R&D Investments Expected to Drive Growth |
20-Jul-2005 |
| The Medicines Company to Announce Second Quarter 2005 Financial Results on Wednesday, July 20, 2005; Conference Call to be Held at 8:30 am EDT |
13-Jul-2005 |
| FDA Approves Expansion of the Medicines Company's Angiomax-R- -Bivalirudin- Label; Prescribing Information Now Includes Data from REPLACE-2 Trial |
15-Jun-2005 |
| The Medicines Company to Present at Pacific Growth Equities |
31-May-2005 |
| The Medicines Company to Present at UBS and Needham |
16-May-2005 |
| The Medicines Company Scheduled to Present at Two Investor Conferences |
26-Apr-2005 |
| The Medicines Company Reports First Quarter 2005 Financial Results |
20-Apr-2005 |
| The Medicines Company First Quarter 2005 Financial Results Conference Call Notice for April 20 |
13-Apr-2005 |
| The Medicines Company Appoints Elizabeth Wyatt to Board of Directors |
5-Apr-2005 |
| The Medicines Company Scheduled to Present at CIBC Conference April 4 |
29-Mar-2005 |
| The Medicines Company Voluntarily Suspends Enrollment In Clevelox--TM-- --Clevidipine-- Safety Trials |
28-Mar-2005 |
| European Society of Cardiology Guidelines Recommend Bivalirudin -Angiox, Angiomax- Replace Heparins in PCI |
17-Mar-2005 |
| The Medicines Company is Scheduled to Present at Two Investor Conferences |
25-Feb-2005 |
| The Medicines Company Reports Fourth Quarter and Year 2004 Financial Results; 69% Revenue Growth from 2003 to 2004 Brings Year of Profitability |
23-Feb-2005 |
| The Medicines Company Fourth Quarter and Full Year 2004 Financial Results Conference Call Notice for February 23 |
16-Feb-2005 |
| The Medicines Company Scheduled to Present at JPMorgan Healthcare Conference |
5-Jan-2005 |
| The Medicines Company Completes Angiomax -Bivalirudin- Phase III Safety Trials in Cardiac Surgery |
28-Dec-2004 |
| The Medicines Company's Second Pivotal Efficacy Trial of Clevelox -Clevidipine- Meets Objectives; Clevelox ESCAPE-1 Trial Demonstrates Blood Pressure Lowering Effect |
16-Dec-2004 |
| The Medicines Company Appoints John Kelley as President and Chief Operating Officer |
2-Dec-2004 |
| The Medicines Company Schedules Webcast of November 11 Investor Briefing |
4-Nov-2004 |
| The Medicines Company Scheduled to Present at CIBC Conference |
3-Nov-2004 |
| The Medicines Company's Angiomax-R- -Bivalirudin- Saves Hospital Costs, Says Publication in Journal of the American College Of Cardiology |
2-Nov-2004 |
| First Hospital Sales of the Medicines Company's Angiox -Bivalirudin- in Europe |
28-Oct-2004 |
| The Medicines Company Clarifies 2004 Guidance, Increasing Revenue Forecast |
19-Oct-2004 |
| The Medicines Company Reports Third Quarter Financial Results; Third Quarter Net Revenue of $37.7 Million - up 77% Compared to 2003 Period |
19-Oct-2004 |
| The Medicines Company Third Quarter 2004 Financial Results Conference Call Notice for October 19 |
12-Oct-2004 |
| The Medicines Company Scheduled to Present at UBS Global Life Sciences Conference |
22-Sep-2004 |
| The Medicines Company Receives Approval to Market Angiox -Bivalirudin- in Europe; European Launches Expected in Fourth Quarter 2004 |
22-Sep-2004 |
| The Medicines Company Scheduled to Present at Bear Stearns Conference |
7-Sep-2004 |
| Journal of the American Medical Association Publishes Long-Term Efficacy Results of The Medicines Company's Angiomax-R- bivalirudin |
10-Aug-2004 |
| The Medicines Company Announces Management Changes And Appointments |
2-Aug-2004 |
| The Medicines Company Reports Second Quarter and First Half 2004 Financial Results |
20-Jul-2004 |
| The Medicines Company Second Quarter 2004 Financial Results Conference Call Notice for July 20 |
13-Jul-2004 |
| European Scientific Committee Recommends Approval Of The Medicines Company's Angiox --Bivalirudin-- |
24-Jun-2004 |
| The Medicines Company Scheduled to Present at Needham Biotechnology Conference |
10-Jun-2004 |
| The Medicines Company Scheduled to Present at Pacific Growth Equities Conference |
4-Jun-2004 |
| The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing |
3-Jun-2004 |
| The Medicines Company Scheduled to Present at Upcoming Investor Conferences |
18-May-2004 |
| The Medicines Company Scheduled to Present at Upcoming Investor Conferences |
23-Apr-2004 |
| The Medicines Company Reports First Quarter 2004 Financial Results; 87% Revenue Growth from First Quarter 2003 to First Quarter 2004; Earnings of $4.2 Million in Quarter |
20-Apr-2004 |
| The Medicines Company First Quarter Financial Results Conference Call Notice for April 20 |
13-Apr-2004 |
| The Medicines Company Announces Publication of First Ever Randomized Clinical Trial Assessing Replacement for Heparin in CABG Surgery |
4-Mar-2004 |
| The Medicines Company Reports Fourth Quarter and Full Year 2003 Financial Results |
10-Feb-2004 |
| The Medicines Company Fourth Quarter and Full Year 2003 Financial Results Conference Call Notice for February 10 |
3-Feb-2004 |
| The Medicines Company to Present at the 11th Annual Emerald Groundhog Day Investment Forum |
30-Jan-2004 |
| The Medicines Company Will Present at JP Morgan Healthcare Conference |
6-Jan-2004 |
| The Medicines Company Acquires Cangrelor, Short-Acting Intravenous Antiplatelet Agent, from AstraZeneca |
18-Dec-2003 |
| The Medicines Company To Provide Financial Guidance for 2004 on December 17 Webcast |
4-Dec-2003 |
| Multimedia Available: The Medicines Company's REPLACE-2 Trial One-Year Mortality Data Presented at American Heart Association's 2003 Scientific Sessions |
11-Nov-2003 |
| The Medicines Company's REPLACE-2 Trial One-Year Mortality Data Presented at American Heart Association's 2003 Scientific Sessions |
11-Nov-2003 |
| The Medicines Company Announces Webcasts of REPLACE-2 One-Year Mortality Review and CIBC Conference Presentation |
7-Nov-2003 |
| The Medicines Company Reports Third Quarter 2003 Financial Results |
21-Oct-2003 |
| The Medicines Company Third Quarter Financial Results Conference Call Notice for October 21 |
15-Oct-2003 |
| The Medicines Company to Present at UBS Global Life Sciences Conference |
22-Sep-2003 |
| Six Month Data from the Medicines Company's Replace-2 Trial of Angiomax -Bivalirudin- Released at TCT |
15-Sep-2003 |
| The Medicines Company's REPLACE-2 Trial Six-Month Findings to Be Featured at TCT 2003 on September 15 |
3-Sep-2003 |
| The Medicines Company to Present at Newsmakers and Bear Stearns Conferences |
2-Sep-2003 |
| The Medicines Company to Present at Adams, Harkness & Hill's 23rd Annual Summer Seminar |
6-Aug-2003 |
| The Medicines Company Submits Angiomax -Bivalirudin- Supplemental NDA With U.S. FDA |
4-Aug-2003 |
| The Medicines Company Submits Application to Market Bivalirudin -Angiomax in U.S.- in Europe |
4-Aug-2003 |
| The Medicines Company Reports Second Quarter 2003 and Mid-Year Financial Results |
22-Jul-2003 |
| The Medicines Company Second Quarter Financial Results Conference Call Notice for July 22 |
15-Jul-2003 |
| Dr. Gary Roubin, World Renowned Interventional Cardiologist, to Spend One-Year Sabbatical Working with The Medicines Company |
23-Jun-2003 |
| Ellen Gudewill Joins the Medicines Company as Vice President Commercial Operations |
12-Jun-2003 |
| The Medicines Company Strengthens New Jersey Presence with New Parsippany Headquarters |
4-Jun-2003 |
| The Medicines Company Receives Approval for Chemilog, Second Generation Angiomax -Bivalirudin- Manufacturing Process |
27-May-2003 |
| The Medicines Company Accelerates Clevidipine Agreement with AstraZeneca, Acquires Exclusive Rights |
19-May-2003 |
| CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast The Medicines Company Presentation |
29-Apr-2003 |
| The Medicines Company Announces New Appointments to Board of Directors |
23-Apr-2003 |
| The Medicines Company Reports First Quarter 2003 Financial Results |
22-Apr-2003 |
| The Medicines Company First Quarter Financial Results Conference Call Notice for April 22 |
15-Apr-2003 |
| Company Profile for The Medicines Company |
11-Apr-2003 |
| REPLACE-2 Clinical Trial Economic Analysis Meets All Endpoints Demonstrating Significant Cost Advantages for the Medicines Company's Angiomax--Bivalirudin-- |
31-Mar-2003 |
| Interventional Cardiologist Dr. Rick McClure Joins The Medicines Company |
28-Mar-2003 |
| The Medicines Company's Angiomax -Bivalirudin- Activities at American College of Cardiology Conference |
25-Mar-2003 |
| The Medicines Company to Present at Banc of America Securities Healthcare Conference |
25-Mar-2003 |
| The Medicines Company Announces Pricing of Follow-on Offering |
14-Mar-2003 |
| The Medicines Company Announces Public Offering of 4,000,000 Shares of Common Stock |
5-Mar-2003 |
| Study Published in Journal of the American Medical Association Validates Angiomax -Bivalirudin- as a New Standard of Care for Angioplasty Treatment |
18-Feb-2003 |
| The Medicines Company Reports Fourth Quarter and Full Year 2002 Financial Results |
11-Feb-2003 |
| The Medicines Company Fourth Quarter Financial Results Conference Call Notice for February 11 |
4-Feb-2003 |
| The Medicines Company to Present at Emerald Investment Forum |
31-Jan-2003 |
| The Medicines Company Presents at J.P. Morgan H&Q Conference |
3-Jan-2003 |
| The Medicines Company To Provide Corporate Update and Investor Guidance Via Webcast and Conference Call |
11-Dec-2002 |
| The Medicines Company's REPLACE-2 Clinical Trial Meets Primary and Secondary Endpoints for Angiomax -bivalirudin- |
17-Nov-2002 |
| The Medicines Company To Host Conference Call On November 17 to Discuss REPLACE-2 Trial Results |
11-Nov-2002 |
| The Medicines Company and Oryx Pharmaceuticals Sign Agreement for Canadian Marketing Rights to Angiomax -Bivalirudin-, a Direct Thrombin Inhibitor for Coronary Angioplasty |
30-Oct-2002 |
| The Medicines Company to Present at Banking Conferences on October 28 and November 4 |
24-Oct-2002 |
| The Medicines Company Reports Third Quarter 2002 Financial Results |
22-Oct-2002 |
| The Medicines Company Third Quarter Financial Results Conference Call Notice for October 22 |
15-Oct-2002 |
| The Medicines Company Receives Approval to Market Angiomax -Bivalirudin- in Canada |
9-Oct-2002 |
| Angiomax --Bivalirudin-- the Focus of Several Presentations At TCT, World's Largest Interventional Cardiology Conference |
23-Sep-2002 |
| The Medicines Company To Present At Bear Stearns 15th Annual Healthcare Conference |
16-Sep-2002 |
| The Medicines Company Completes Enrollment of 6000-Patient REPLACE-2 Angioplasty Trial |
27-Aug-2002 |
| The Medicines Company Reports Second Quarter 2002 Financial Results and Confirms Annual Guidance |
23-Jul-2002 |
| The Medicines Company Second Quarter Financial Results and Conference Call Notice for July 23 |
11-Jul-2002 |
| Results From The Medicines Company's CACHET Trial Published in American Heart Journal |
9-Jul-2002 |
| The Medicines Company Announces Offering |
20-Jun-2002 |
| UBS Warburg to Webcast The Medicines Company's Corporate Presentation |
4-Jun-2002 |
| Articles Published in the Medical Journals 'Anesthesiology' and 'Experimental Hypertension' Affirm Potential for Clevidipine |
21-May-2002 |
| CIBC World Markets to Webcast the Medicines Company's Corporate Presentation |
1-May-2002 |
| The Medicines Company Files Shelf Registration Statement |
23-Apr-2002 |
| The Medicines Company Reports First Quarter 2002 Financial Results, Names New Chief Financial Officer |
23-Apr-2002 |
| The Medicines Company First Quarter Financial Results and Conference Call Notice |
9-Apr-2002 |
| ANGIOMAX -- bivalirudin -- Assigned Medicare Ambulatory Payment Classification Code |
1-Apr-2002 |
| The Medicines Company Receives Approvable Letter for Second Generation ANGIOMAX -- bivalirudin -- Manufacturing Process |
27-Mar-2002 |
| The Medicines Company Signs Collaboration for ANGIOMAX --bivalirudin-- in Europe Including Russia/CIS; Agreement With Nycomed to Cover 35 Countries |
27-Mar-2002 |
| The Medicines Company Announces Results of Phase II Bacterial Vaginosis Study |
26-Mar-2002 |
| The Medicines Company Announces Acquisition of Rights to Clevidipine; Phase 3 Drug Candidate to be Tested for Use in Hospital Hypertension Patients |
6-Mar-2002 |
| The Medicines Company Reports Fourth Quarter and Full Year 2001 Financial Results |
12-Feb-2002 |
| ANGIOMAX -- Bivalirudin -- Acute Coronary Syndromes Data Published in the American Heart Journal; Article's Findings Reaffirm Unique Risk/Benefit Profile of ANGIOMAX |
12-Feb-2002 |
| The Medicines Company Fourth Quarter and Full Year Financial Results and Conference Call Notice |
1-Feb-2002 |
| Lancet Meta-analysis Finds ANGIOMAX (bivalirudin) and Other Direct Thrombin Inhibitors are More Effective Than Heparin |
30-Jan-2002 |
| US Bancorp Piper Jaffray to Webcast The Medicines Company's Corporate Presentation |
29-Jan-2002 |
| The Medicines Company Signs Agreement to Sell ANGIOMAX (bivalirudin) in Australia; ANGIOMAX Now Licensed in 23 Countries Around the World |
8-Jan-2002 |
| JP Morgan H&Q Healthcare Conference to Webcast the Medicines Company's Corporate Presentation |
8-Jan-2002 |
| ANGIOMAX --bivalirudin-- Angioplasty Data Published in The American Heart Journal; Authors Conclude ANGIOMAX Risk-Benefit Ratio May be Unique Among Anticoagulants |
30-Nov-2001 |
| The Medicines Company Reports Third Quarter 2001 Financial Results |
24-Oct-2001 |
| The Medicines Company Third Quarter Financial Results and Conference Call Notice |
19-Oct-2001 |
| The Medicines Company Updates Revenue Guidance |
3-Oct-2001 |
| The Medicines Company Strengthens Senior Management Team; Meanwell Continues to Lead Company as Executive Chairman; Stack Assumes Full-Time Role as President and CEO |
25-Sep-2001 |
| The Medicines Company Reports Results From HERO-2 Trial: An International Clinical Study in Heart Attack Patients |
2-Sep-2001 |
| The Medicines Company HERO-2 Results Conference Calls Notice |
31-Aug-2001 |
| The Medicines Company Reports Second Quarter 2001 Financial Results |
25-Jul-2001 |
| The Medicines Company Second Quarter Financial Results and Conference Call Notice |
16-Jul-2001 |
| The Medicines Company Announces Key Appointments |
21-Jun-2001 |
| The Medicines Company Announces Part One Clinical Results and Part Two Design of the REPLACE Program |
8-Jun-2001 |
| The Medicines Company Signs Collaboration for ANGIOMAX - Bivalirudin - in Key Latin American and European Territories |
5-Jun-2001 |
| The Medicines Company Signs Agreement to Sell Angiomax¨ (bivalirudin) in Israel |
21-May-2001 |
| The Medicines Company Announces $44 Million Private Placement of Common Stock |
11-May-2001 |
| The Medicines Company Reports First Quarter 2001 Financial Results |
25-Apr-2001 |
| The Medicines Company 2001 First Quarter Financial Results News Release and Conference Call Notice |
19-Apr-2001 |
| The Medicines Company Announces Registration Statement Withdrawal |
18-Mar-2001 |
| The Medicines Company Reports Fourth Quarter and Full Year 2000 Financial Results |
14-Feb-2001 |
| The Medicines Company Fourth Quarter and Year End Results News Release and Conference Call Notice |
7-Feb-2001 |
| The Medicines Company Fourth Quarter and Year End Results News Release and Conference Call Notice |
7-Feb-2001 |
| The Medicines Company Announces Additional Lock-Up in Connection with Proposed Follow-On Public Offering |
5-Jan-2001 |
| The Medicines Company Files Registration Statement for Proposed Follow-On Public Offering |
5-Jan-2001 |
 |
